

Experimental approaches in personalised medicine in urothelium tumours

Poster Session 39

Sunday, 26 March
14:00 - 15:30

Location: Room Madrid, North Hall (Level 1)

Chairs: F. Deho, Milan (IT)
M. Knowles, Leeds (GB)
M. Sanchez-Carbayo, Vitoria-Gasteiz (ES)

Aims and objectives of this session

The course of bladder cancer could be affected by many factors. In order to predict the course of the disease, it is important to analyze multiple parameters. Studies presented in this session will focus also on exosomes and miRNA.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

- *519 **Tumor-associated exosomes of urothelial bladder cancer cells affect tumor-promoting processes in normal bladder fibroblasts and support tumorigenesis**
By: Baumgart S.¹, Heinzelmann J.¹, Krause E.², Stöckle M.¹, Stampe Ostenfeld M.³, Junker K.¹
Institutes:¹Saarland University Medical Center, Dept. of Urology, Homburg, Germany, ²Saarland University Medical Center, Dept. of Physiology, Homburg, Germany, ³University Hospital Aarhus, Dept. of Molecular Medicine, Aarhus, Denmark
- 520 **Cancer-associated fibroblasts secreted exosomal miR-146a promotes bladder cancer progression**
By: Zhuang J.¹, Shen L.², Yan J.², Guo H.¹
Institutes:¹Nanjing University Medical School Affiliated Nanjing Drum Tower Hospital, Dept. of Urology, Nanjing, China, ²MOE Key Laboratory of Model Animals For Disease Study, Model Animal Research Center, Dept. of Tumor Biology, Nanjing, China
- 521 **Genomic landscape of upper urinary tract urothelial carcinoma**
By: Fujii Y.¹, Sato Y.¹, Suzuki H.², Shiozawa Y.², Yoshizato T.², Yoshida K.², Shiraishi Y.³, Nakagawa T.¹, Kume H.¹, Nishimatsu H.⁴, Okaneya T.⁵, Sanada M.⁶, Makishima H.², Miyano S.³, Ogawa S.², Homma Y.¹
Institutes:¹The University Of Tokyo Hospital, Dept. of Urology, Bunkyo, Japan, ²Graduate School of Medicine Kyoto University, Dept. of Pathology and Tumor Biology, Kyoto, Japan, ³Institute of Medical Science The University of Tokyo, Laboratory of DNA Information Analysis, Human Genome Center, Minato, Japan, ⁴The Fraternity Memorial Hospital, Dept. of Urology, Sumida, Japan, ⁵Toranomon Hospital, Dept. of Urology, Minato, Japan, ⁶Nagoya Medical Center, Advanced Diagnosis, Clinical Reserach Center, Nagoya, Japan
- *522 **Molecular subtype classification of advanced bladder cancer and matched lymph-node metastases by integrative immunohistochemistry, gene expression, and mutation analyses**
By: Sjö Dahl G.¹, Eriksson P.², Lövgren K.², Liedberg F.¹, Höglund M.²
Institutes:¹Translational Medicine, Dept. of Urologic Research, Lund, Sweden, ²Clinical Sciences, Dept. of Oncology and Pathology, Lund, Sweden
- 523 **Withdrawn**
By:
Institutes:
- 524 **Urine based DNA methylation biomarkers for monitoring bladder cancer**
By: Van Der Heijden A.², Mengual L.¹, Ingelmo-Torres M.¹, Lozano J.³, Van Rijt-Van De Westerlo C.⁴,

Santos P.¹, Geavlete B.⁵, Moldoveanu C.⁵, Ene C.⁵, Dinney C.⁶, Czerniak B.⁷, Schalken J.⁴, Kiemeneý L.⁸, Ribal M.¹, Witjes J.², Alcaraz A.¹

Institutes:¹Hospital Clinic, IDIBAPS, Dept. of Urology, Barcelona, Spain, ²Radboudumc, Dept. of Urology, Nijmegen, The Netherlands, ³Hospital Clinic, CIBERehd, IDIBAPS, Barcelona, Spain, ⁴Radboudumc, Dept. of Experimental Urology, Nijmegen, The Netherlands, ⁵Saint John Emergency Clinical Hospital, Dept. of Urology, Bucharest, Romania, ⁶MD Anderson Cancer Center, Dept. of Urology, Houston, Texas, United States of America, ⁷MD Anderson Cancer Center, Dept. of Pathology, Houston, Texas, United States of America, ⁸Radboudumc, Dept. of Health Evidence, Nijmegen, The Netherlands

525 **Utilization of next-generation sequencing techniques to investigate markers for chemosensitivity in bladder cancer patients treated with neoadjuvant chemotherapy prior to radical cystectomy**

By: Boström P.¹, Fey V.², Kaikkonen E.³, Lamminen T.¹, Laitinen A.¹, Mirtti T.⁴, Koskinen I.⁵, Salminen A.¹, Taimen P.⁶, Schleutker J.³

Institutes:¹Turku University Hospital, Dept. of Urology, Turku, Finland, ²University of Turku, Institution of Biotechnology, Turku, Finland, ³Turku University, Dept. of Medical Biochemistry and Genetics, Turku, Finland, ⁴Helsinki University Hospital and Finnish Institute For Molecular Medicine, University of Helsinki, Dept. of Pathology (HUSLAB), Helsinki, Finland, ⁵Helsinki University Hospital, Dept. of Urology, Helsinki, Finland, ⁶Turku University Hospital, Dept. of Pathology, Turku, Finland

526 **Bladder cancer-secreted extracellular vesicles destroy vascular endothelial barriers**

By: Yoneyama M.S.¹, Hatakeyama S.², Funyu T.³, Tsuboi S.¹, Ohyama C.²

Institutes:¹Oyokyo Kidney Research Institute, Dept. of Cancer Immunology and Cell Biology, Hirosaki, Japan, ²Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan, ³Oyokyo Kidney Research Institute, Dept. of Urology, Hirosaki, Japan

527 **KRT5 and KRT20 expression predicts recurrence and progression of stage pT1 non-muscle-invasive bladder cancer (NMIBC)**

By: Breyer J.¹, Wirtz R.², Denzinger S.¹, Erben P.³, Kriegmair M.³, Stoehr R.⁴, Eckstein M.⁴, Burger M.¹, Otto W.¹, Hartmann A.⁴

Institutes:¹University of Regensburg, Dept. of Urology, Regensburg, Germany, ²Stratifyer Molecular Pathology GmbH, Cologne, Germany, ³University Hospital Mannheim, Dept. of Urology, Mannheim, Germany, ⁴University of Erlangen-Nuremberg, Institute of Pathology, Erlangen, Germany

528 **Cell-free DNA from urine samples – a valuable source for bladder cancer biomarkers?**

By: Salomo K., Moritz S., Füssel S., Wirth M.

Institutes:Universitätsklinikum Carl Gustav Carus, Dept. of Urology, Dresden Johannstadt Nord, Germany

529 **SMYD3 drives IGF-1R-AKT pathway activation in bladder cancer**

By: Liu L.¹, Fan Y.², Wang K.², Yan K.², Liu C.²

Institutes:¹Shandong University, School of Nursing, Jinan, China, ²Shandong University Qilu Hospital, Dept. of Urology, Jinan, China

530 **Her2 alterations in muscle-invasive bladder cancer: There is more than protein expression in patient selection for targeted therapy**

By: Kiss B.², Wyatt A.³, Douglas J.⁴, Skuginna V.², Mo F.³, Anderson S.³, Rotzer D.², Fleischmann A.⁵, Genitsch V.⁵, Hayashi T.⁶, Neuenschwander M.⁵, Bürki C.⁷, Davicioni E.⁷, Collins C.³, Thalmann G.², Black P.³, Seiler R.¹

Institutes:¹Universitätsspital Bern, Universitätsklinik für Urologie, Bern, Switzerland, ²University of Bern, Dept. of Urology, Bern, Switzerland, ³University of British Columbia, Dept. of Urologic Sciences, Vancouver, Canada, ⁴University Hospital of Southampton, Dept. of Urology, Hampshire, United Kingdom, ⁵University of Bern, Institute of Pathology, Bern, Switzerland, ⁶Hiroshima University, Dept. of Urology, Hiroshima, Japan, ⁷GenomeDx, Biosciences, Vancouver, Canada

15:15 - 15:25

Molecular subtypes urothelial cancer

M. Sanchez-Carbayo, Vitoria-Gasteiz (ES)